Post-operative Locoregional Irradiation Using Helical Tomotherapy IMRT in the Management of Stage IIb-III Breast Cancer: a Feasibility Study
The role of locoregional radiation therapy in the management of stage IIB and III breast
cancer has evolved and continues to evolve. The exact role of locoregional radiation,
including axillary, supraclavicular and internal mammary nodes is, however, not clear.
Radiation-induced toxicity remains a limiting factor to expanding the indications for
radiation therapy to axillary and internal mammary nodes in the treatment of stage IIB and
III breast cancer. Excellent target coverage and normal tissue sparing of IMRT has been
previously demonstrated dosimetrically and clinically. In this feasibility study, patients
will receive 50 Gy of radiation therapy in 25 fractions to the chest wall and
supraclavicular, axillary and IM nodal areas using HT-IMRT following breast conserving
surgery or mastectomy and chemotherapy. Patients will also be eligible for a radiation
boost to 12 Gy by HT-IMRT or HDR brachytherapy. It is expected that treatment with HT-IMRT
will result in appreciably fewer side-effects following locoregional irradiation due to a
reduction in normal tissue irradiation, as compared to conventional radiation therapy.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Acute radiation effects(less than 90 days post treatment)
less than 90 days post treatment
Yes
Jean-Michel Caudrelier, md
Principal Investigator
OHRI
Canada: Health Canada
2006277-01H
NCT00508352
January 2007
October 2009
Name | Location |
---|